82 related articles for article (PubMed ID: 16508919)
1. Expression of drug pathway proteins is independent of tumour type.
Zhang W; Shannon WD; Duncan J; Scheffer GL; Scheper RJ; McLeod HL
J Pathol; 2006 Jun; 209(2):213-9. PubMed ID: 16508919
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical profile of the sodium/iodide symporter in thyroid, breast, and other carcinomas using high density tissue microarrays and conventional sections.
Wapnir IL; van de Rijn M; Nowels K; Amenta PS; Walton K; Montgomery K; Greco RS; Dohán O; Carrasco N
J Clin Endocrinol Metab; 2003 Apr; 88(4):1880-8. PubMed ID: 12679487
[TBL] [Abstract][Full Text] [Related]
3. WIF1, a component of the Wnt pathway, is down-regulated in prostate, breast, lung, and bladder cancer.
Wissmann C; Wild PJ; Kaiser S; Roepcke S; Stoehr R; Woenckhaus M; Kristiansen G; Hsieh JC; Hofstaedter F; Hartmann A; Knuechel R; Rosenthal A; Pilarsky C
J Pathol; 2003 Oct; 201(2):204-12. PubMed ID: 14517837
[TBL] [Abstract][Full Text] [Related]
4. Expression and localization of Reg IV in human neoplastic and non-neoplastic tissues: Reg IV expression is associated with intestinal and neuroendocrine differentiation in gastric adenocarcinoma.
Oue N; Mitani Y; Aung PP; Sakakura C; Takeshima Y; Kaneko M; Noguchi T; Nakayama H; Yasui W
J Pathol; 2005 Oct; 207(2):185-98. PubMed ID: 16086444
[TBL] [Abstract][Full Text] [Related]
5. The Wnt pathway regulator DKK1 is preferentially expressed in hormone-resistant breast tumours and in some common cancer types.
Forget MA; Turcotte S; Beauseigle D; Godin-Ethier J; Pelletier S; Martin J; Tanguay S; Lapointe R
Br J Cancer; 2007 Feb; 96(4):646-53. PubMed ID: 17245340
[TBL] [Abstract][Full Text] [Related]
6. Irinotecan in lymphoma, leukemia, and breast, pancreatic, ovarian, and small-cell lung cancers.
Rosen LS
Oncology (Williston Park); 1998 Aug; 12(8 Suppl 6):103-9. PubMed ID: 9726101
[TBL] [Abstract][Full Text] [Related]
7. Expression of p27kip1 in breast cancer and its prognostic significance.
Barnes A; Pinder SE; Bell JA; Paish EC; Wencyk PM; Robertson JF; Elston CW; Ellis IO
J Pathol; 2003 Nov; 201(3):451-9. PubMed ID: 14595757
[TBL] [Abstract][Full Text] [Related]
8. Relationship of arachidonic acid metabolizing enzyme expression in epithelial cancer cell lines to the growth effect of selective biochemical inhibitors.
Hong SH; Avis I; Vos MD; Martínez A; Treston AM; Mulshine JL
Cancer Res; 1999 May; 59(9):2223-8. PubMed ID: 10232612
[TBL] [Abstract][Full Text] [Related]
9. Glucuronidation of SN-38 and NU/ICRF 505 in human colon cancer and adjacent normal colon.
Cummings J; Ethell BT; Jardine L; Burchell B
Anticancer Res; 2006; 26(3B):2189-96. PubMed ID: 16821585
[TBL] [Abstract][Full Text] [Related]
10. Differentiated human colorectal cancer cells protect tumor-initiating cells from irinotecan.
Emmink BL; Van Houdt WJ; Vries RG; Hoogwater FJ; Govaert KM; Verheem A; Nijkamp MW; Steller EJ; Jimenez CR; Clevers H; Borel Rinkes IH; Kranenburg O
Gastroenterology; 2011 Jul; 141(1):269-78. PubMed ID: 21459094
[TBL] [Abstract][Full Text] [Related]
11. Enhancing the anticancer efficacy of camptothecin using biotinylated poly(ethylene glycol) conjugates in sensitive and multidrug-resistant human ovarian carcinoma cells.
Minko T; Paranjpe PV; Qiu B; Lalloo A; Won R; Stein S; Sinko PJ
Cancer Chemother Pharmacol; 2002 Aug; 50(2):143-50. PubMed ID: 12172980
[TBL] [Abstract][Full Text] [Related]
12. Detection of HER2 amplification using the SISH technique in breast, colon, prostate, lung and ovarian carcinoma.
Ramieri MT; Murari R; Botti C; Pica E; Zotti G; Alo PL
Anticancer Res; 2010 Apr; 30(4):1287-92. PubMed ID: 20530441
[TBL] [Abstract][Full Text] [Related]
13. Expression of multidrug-resistance-related proteins P-glycoprotein, glutathione-S-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma.
Shi H; Lu D; Shu Y; Shi W; Lu S; Wang K
Cancer Invest; 2008 May; 26(4):344-51. PubMed ID: 18443954
[TBL] [Abstract][Full Text] [Related]
14. Imaging mass spectrometry: principles and potentials.
Chaurand P; Schwartz SA; Reyzer ML; Caprioli RM
Toxicol Pathol; 2005; 33(1):92-101. PubMed ID: 15805060
[TBL] [Abstract][Full Text] [Related]
15. [Clinical activity spectrum of irinotecan].
Cottu PH; Extra JM; Lerebours F; Espie M; Marty M
Bull Cancer; 1998 Dec; Spec No():21-5. PubMed ID: 9932080
[TBL] [Abstract][Full Text] [Related]
16. Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan.
Xu G; Zhang W; Ma MK; McLeod HL
Clin Cancer Res; 2002 Aug; 8(8):2605-11. PubMed ID: 12171891
[TBL] [Abstract][Full Text] [Related]
17. Peptide and protein imaging mass spectrometry in cancer research.
McDonnell LA; Corthals GL; Willems SM; van Remoortere A; van Zeijl RJ; Deelder AM
J Proteomics; 2010 Sep; 73(10):1921-44. PubMed ID: 20510389
[TBL] [Abstract][Full Text] [Related]
18. Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein.
de Jong FA; Scott-Horton TJ; Kroetz DL; McLeod HL; Friberg LE; Mathijssen RH; Verweij J; Marsh S; Sparreboom A
Clin Pharmacol Ther; 2007 Jan; 81(1):42-9. PubMed ID: 17185998
[TBL] [Abstract][Full Text] [Related]
19. A comparison of p21 and p27 immunoexpression in benign glands, prostatic intraepithelial neoplasia and prostate adenocarcinoma.
Doganavsargil B; Simsir A; Boyacioglu H; Cal C; Hekimgil M
BJU Int; 2006 Mar; 97(3):644-8. PubMed ID: 16469041
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical expression of topoisomerase IIalpha (Topo IIalpha) and multidrug resistance-associated protein (MRP), plus chemosensitivity testing, as chemotherapeutic indices of ovarian and endometrial carcinomas.
Koshiyama M; Fujii H; Kinezaki M; Morita Y; Nanno H; Yoshida M
Anticancer Res; 2001; 21(4B):2925-32. PubMed ID: 11712788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
